Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Tetrabuthylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A1 | O15245 | 4/20 | 0.75 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tetrabuthylammonium SCHEMBL29119812 | 0.90 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL1473709 | 0.90 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL5841582 | 0.90 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL9117 | 0.90 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL28454683 | 0.90 | SLC22A1 (0.92) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL28338553 | 0.88 | SLC22A1 (0.75) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL28731415 | 0.88 | SLC22A1 (0.75) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL23202726 | 0.87 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL3169343 | 0.87 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 | |
| Tetrabuthylammonium SCHEMBL10577668 | 0.87 | SLC22A1 (0.86) | SLC22A1SLC22A2ALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180516-B2 | Phosphine transition metal complex, method for producing same, and anticancer agent | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-11-23 | — | — | US | disclosed |
| US-20210253612-A1 | PHOSPHINE TRANSITION METAL COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2021-08-19 | — | — | US | disclosed |
| US-20200247833-A1 | METHOD FOR PRODUCING 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, AND METHOD FOR PRODUCING PHOSPHINE TRANSITION METAL COMPLEX | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2020-08-06 | — | — | US | disclosed |
| US-10111892-B2 | Anti-cancer agent | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2018-10-30 | — | — | US | disclosed |
| EP-1876182-B1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | NIPPON CHEMICAL IND (JP) | 2012-12-19 | — | — | EP | disclosed |
| US-20120252762-A1 | ANTI-CANCER AGENT | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-10-04 | — | — | US | disclosed |
| EP-2502627-A1 | ANTI-CANCER AGENT | Nippon Chemical Industrial Co., Ltd. (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-8106186-B2 | Transition metal phosphine complex, method for producing same, and anticancer agent containing transition metal phospine complex | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | NIPPON CHEMICAL INDUSTRIAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| EP-1958951-A1 | PHOSPHINE TRANSITION METAL COMPLEX, METHOD FOR PRODUCING SAME AND ANTITUMOR AGENT CONTAINING SAME | Nippon Chemical Industrial Co., Ltd. (JP) | 2008-08-20 | — | — | EP | disclosed |
| EP-1876182-A1 | PHOSPHINE TRANSITION METAL COMPLEX, PROCESS FOR PRODUCING THE SAME AND ANTICANCER DRUG CONTAINING THE SAME | Nippon Chemical Industrial Co., Ltd. (JP) | 2008-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076267-A1 | TRANSITION METAL PHOSPHINE COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT CONTAINING TRANSITION METAL PHOSPINE COMPLEX | CDKL1, MASTL, AARS1 | SLC22A1 2511/4885SLC22A2 2700/4885ALDH1A1 2521/4885 |
| US-20200247833-A1 | METHOD FOR PRODUCING 2,3-BISPHOSPHINOPYRAZINE DERIVATIVE, AND METHOD FOR PRODUCING PHOSPHINE TRANSITION METAL COMPLEX | BPGM, PPIP5K2, BMP2 | SLC22A1 1103/4885SLC22A2 856/4885ALDH1A1 2388/4885 |
| US-11180516-B2 | Phosphine transition metal complex, method for producing same, and anticancer agent | PRMT9, MCL1, MRPS9 | SLC22A1 2616/4885SLC22A2 3035/4885ALDH1A1 3878/4885 |
| US-10111892-B2 | Anti-cancer agent | MCL1, ROS1, SRSF1 | SLC22A1 1424/4885SLC22A2 2690/4885ALDH1A1 703/4885 |
| US-20120252762-A1 | ANTI-CANCER AGENT | MCL1, SRSF1, ROS1 | SLC22A1 1388/4885SLC22A2 2648/4885ALDH1A1 735/4885 |
| US-20210253612-A1 | PHOSPHINE TRANSITION METAL COMPLEX, METHOD FOR PRODUCING SAME, AND ANTICANCER AGENT | PRMT9, MCL1, MRPS9 | SLC22A1 2616/4885SLC22A2 3035/4885ALDH1A1 3878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.